Parkinson’s disease

Summer School Health and Wealth WEB Seminars – Converging pathways in Alzheimer and Parkinson’s disease: management strategies and disease modifying treatment

The main objective of World Brain Day is to increase public awareness and promote advocacy related to brain health.

On this World Brain Day, watch interviews with specialists and patients regarding Parkinson´s Disease.

Professor Tissa Wijeratne and Professor Wolfgang Grisold have teamed up on an expert article for the World Brain Day "Move together to End Parkinson's Disease".

Neural basis of impulse control behaviours in Parkinson’s disease

MDS-ES 8th Winter School for Young Neurologists at King’s College in London Almost 50 young neurologists and neurology residents from all over the world gathered in London from 7-9 February for the 8th Movement Disorder Society (MDS) Winter School for young neurologists. This well-attended and lively event featured two-and-half days of presentations, focused clinical examination rounds, video sessions and debate, driven by plenary sessions and two parallel workshops.

For January 2019, we have selected: Killinger BA, Madaj Z, Sikora JW, et al. The vermiform appendix impacts the risk of developing Parkinson’s disease. Sci Transl Med 2018,10:1-15.

The November issue of the European Journal of Neurology is online!

  The XXIII World Congress of the International Association of Parkinson’s Disease and Related Disorders (IAPRD) was held from August 19th to 22th, 2018, in Lyon, France, at the Lyon Convention Centre, a beautiful location designed by the famous Italian… Continue Reading

For September 2018, we have selected:  Katzenschlager R, Poewe W, Rascol O, et al. Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persisten motor fluctuations (TOLEDO): a multicenter, double-blind, randomized, placebo-controlled trial. Lancet Neurol July 25, 2018. doi:10.1016/S1474-4422(18)30284-4. Subcutaneous infusion of apomorphine, a potent dopamine receptor agonist, is widely used in patients with Parkinson’s disease (PD) with motor fluctuations not optimally controlled with oral medication, but the previous evidence base to support this approach was weak, derived from open label studies.

he Congress will begin each morning and afternoon with Plenary Sessions providing overviews of the phenomenology, pathophysiology, and current diagnostic and therapeutic strategies of various movement disorders. These sessions will be followed by Parallel Tracks, permitting participants to select specific diagnostic or therapeutic areas for more concentrated study.

I would like to state my deepest gratitude and appreciation to the European Academy of Neurology for having granted me the research-training fellowship for 12 months at Prof. Benazzouz Abdelhamid’s research group, at the Institute of Neurodegenerative disease, Bordeaux University, France.

I would like to express my gratitude to the European Academy of Neurology for awarding me with research-experience fellowship at Prof. Bastiaan Bloem’s research group at the Department of Neurology, Radboud University, Nijmegen, The Netherlands.

For August 2018, we have selected: Corvol JC, Artaud F, Cornier-Dequaire F, et al., for the DIGPD Study Group. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology 2018. doi:10.1212/WNL.0000000000005816. Impulse control disorders (ICDs) are frequent in Parkinson’s disease (PD) patients, and can have relevant consequences on social life. Whereas the association between treatment with dopamine agonists (DA) and the onset of ICDs is well known, there is controversy about the relationship with dose and duration of DA therapy.